# A Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC/HPSCC

> **NCT06793761** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Beijing Tongren Hospital** · enrollment: 260 (estimated)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Cisplatin
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT06793761
- **Lead sponsor:** Beijing Tongren Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02-01
- **Primary completion:** 2026-12-20
- **Final completion:** 2028-12-31
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2025-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06793761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06793761, "A Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC/HPSCC". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06793761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*